Literature DB >> 24124

Deoxypyrimidine nucleoside metabolism in varicella-zoster virus-infected cells.

T Hackstadt, L P Mallavia.   

Abstract

Noninfected and varicella-zoster virus (VZV)-infected human foreskin fibroblasts were examined for thymidine kinase activity. The specific activity of VZV-infected cell extracts was approximately 7.5-fold greater than that of mock-infected cells and 3-fold greater than that of actively growing cells. The pH optimum of VZV-infected cell thymidine kinase activity was found to be 8.0, whereas thymidine kinase activity in noninfected cells exhibited a sharp pH optimum at 7.4. Electrophoretic analysis of cellular enzymes involved in pyrimidine nucleoside phosphorylation revealed at least three enzymes distinguishable by electrophoretic mobility and substrates used. These enzymes were presumed to be thymidine kinase, deoxycytidine kinase, and uridine kinase. The relative mobilities of these enzymes on 5% polyacrylamide gels were 0.18, 0.91, and 0.54, respectively. In VZV-infected cells, a single band of activity catalyzing the phosphorylation of thymidine, deoxyuridine, deoxycytidine, and cytidine was observed with a relative mobility of 0.48. Cellular pyrimidine-phosphorylating enzymes were not detected in VZV-infected cells. The molecular weight of the VZV-induced enzyme was determined to be 72,000 +/- 7%.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 24124      PMCID: PMC353963          DOI: 10.1128/JVI.25.2.510-517.1978

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  INHIBITION BY METABOLIC ANALOGUES OF PLAQUE FORMATION BY HERPES ZOSTER AND HERPES SIMPLEX VIRUSES.

Authors:  F RAPP
Journal:  J Immunol       Date:  1964-10       Impact factor: 5.422

2.  DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.

Authors:  B J DAVIS
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

3.  INHIBITION OF VARICELLA VIRUS BY 5-IODO-2'-DEOXYURIDINE.

Authors:  W E RAWLS; R A COHEN; E C HERRMANN
Journal:  Proc Soc Exp Biol Med       Date:  1964-01

4.  Thymidine kinase isozymes of normal and virus-infected cells.

Authors:  S Kit; W C Leung; G N Jorgensen; D Trkula; D R Dubbs
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1975

5.  Viral-induced thymidine kinase isozymes.

Authors:  S Kit; W C Leung; G N Jorgensen; D Trkula; D R Dubbs
Journal:  Prog Med Virol       Date:  1975

6.  Varicella-zoster virus and subcutaneous cytarabine: correlation of in vitro sensitivities to blood levels.

Authors:  D A Zaky; R F Betts; R G Douglas; K Bengali; G L Neil
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

7.  Mitochondrial and herpesvirus-specific deoxypyrimidine kinases.

Authors:  W C Leung; D R Dubbs; D Trkula; S Kit
Journal:  J Virol       Date:  1975-09       Impact factor: 5.103

8.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

9.  Thymidine-kinase in cytomegalovirus infected cells.

Authors:  V Závada; V Erban; D Rezácová; V Vonka
Journal:  Arch Virol       Date:  1976       Impact factor: 2.574

10.  Enzymatic basis for the selective inhibition of varicella-zoster virus by 5-halogenated analogues of deoxycytidine.

Authors:  M J Dobersen; M Jerkofsky; S Greer
Journal:  J Virol       Date:  1976-11       Impact factor: 5.103

View more
  12 in total

1.  Acyclic guanosine analogs as substrates for varicella-zoster virus thymidine kinase.

Authors:  A R Karlström; C F Källander; G Abele; A Larsson
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

2.  Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.

Authors:  T Sakuma
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

3.  In vitro susceptibility of varicella-zoster virus to acyclovir.

Authors:  K K Biron; G B Elion
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

4.  Inhibiting effect of (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture.

Authors:  G Abele; A Karlström; J Harmenberg; S Shigeta; A Larsson; B Lindborg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

5.  In-vitro synthesis of functional varicella zoster and herpes simplex viral thymidine kinase.

Authors:  R Mahalingam; G Cabirac; M Wellish; D Gilden; A Vafai
Journal:  Virus Genes       Date:  1990-07       Impact factor: 2.332

6.  Characterization of a varicella-zoster virus variant with altered thymidine kinase activity.

Authors:  S Shigeta; S Mori; T Yokota; K Konno; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

7.  Purification and biochemical characterization of deoxythymidine kinase of deoxythymidine kinase-deficient mouse 3T3 cells biochemically transformed by equine herpesvirus type 1.

Authors:  J J McGowan; G P Allen; G A Gentry
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

8.  Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment.

Authors:  G B Roberts; J A Fyfe; R K Gaillard; S A Short
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

9.  In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.

Authors:  E De Clercq; J Descamps; M Ogata; S Shigeta
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

10.  Human serum antibodies to varicella-zoster virus thymidine kinase.

Authors:  C F Källander; J S Gronowitz; E G Torfason
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.